Lyka Labs Ltd. — Capital/Financing Update 2023

Jan 21, 2023

Lyka Labs Limited |

Corporate Office : Ground floor, Spencer Building, 30, Forjett Street, Grant Road (West), Mumbai - 400 036 * Phone : 6611 2200/290 Website : www.lykalabs.com « Email : enquiry@lykalabs.com Healthcare Through Innovation

Labs Limited
Corporate Office : Ground floor, Spencer Building, 30, Forjett Street, Grant Road (West), Mumbai - 400 036
* Phone : 6611 2200/290 Website : www.lykalabs.com « Email : enquiry@lykalabs.com	Healthcare Through Innovation
2ist January 2023
The BSE Limited	The National Stock Exchange of India Limited
Ist floor, New Trading Ring	Exchange Plaza, 5t* Floor
Rotunda Bldg, P.J Towers	Plot No. C/1, G. Block
Dalal Street,	Bandra Kurla Complex
Mumbai -400 001.	Bandra (East), Mumbai - 400 051.
Script Code: 500259	Script Code: LYKALABS

Dear Sir/ Madam,

Sub.: Outcome of the Board Meeting held on 21st January 2023

In Compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015; this is to inform you that the Board of Directors at its Meeting held today i.e.21st January 2023 inter alia transacted the following;

1. Issue of Equity Shares and Warrants convertible into Equity Shares on preferential basis to Promoter Group

The Board has approved the raising of funds upto Rs. 100 Crores by issuing, offering and allotting the following securities of the Company to Ipca Laboratories Limited ('Promoter Group') by way of preferential issue:

• a. Upto 20,00,000 Equity Shares of Face value of Rs. 10/- each for cash at a price of Rs. 139.50 per Equity Share, including premium of Rs. 129.50 per Equity Share; and
• b. Upto 50,00,000 convertible warrants with right to the warrant holder to apply for and be allotted One (1) Equity Shares of Face value of Rs. 10/- each of the Company for each Warrants within period of Eighteen (18) months from the date of allotment of warrants at the price of Rs. 139.50 per warrant each convertible into or exchangeable for 1 (one) Equity Share of face value of Rs. 10/- each at premium of Rs. 129.50 per Equity Share.

The information pursuant to Regulation 30 of the SEBI Listing Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015, is enclosed as Annexure-1.

2. Convening of Extra Ordinary General Meeting (EOGM) of the Company

The Board of Directors has decided to convey an EOGM on Friday, 17th February 2023 at 11 a.m. through Video Conferencing (VC)/Other Video Visual Means (OAVM), to seek the approval of shareholders of the Company for the matter specified above and has approved draft Notice of EOGM along with explanatory statement thereto.

The meeting of the Board of Directors commenced at 11 a.m. and concluded at 12: 20 p.m.

We request to take the same on your record.

Thanking You, Yours sincerely,

For Lyka Labs Limited Kishore P. Shah Company Secretary & Compliance Officer Encl.: A/a. Kishore Prafullchandra Shah Digitally signed by Kishore Prafullchandra Shah Date: 2023.01.21 12:31:21 +05'30'

ANNEXURE 1

DETAILS REGARDING PREFERENTIAL ISSUE

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

		ANNEXURE1DETAILS REGARDING PREFERENTIAL ISSUE
		Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
	Sl. PARTICULARS	DESCRIPTION
1.	proposed Typesecuritiesoftobe issued.	Equity Shares1.Warrants Convertible into Equity Shares2.
2.	Type of issuance	Preferential Allotment
3.	Total number of securities proposed to]beissued or the total amount for which the willsecuritiesissued be(approximately)	1. Upto 20,00,000 Equity Shares of Face value ofRs, 10/- each for cash at a price of Rs. 139.50 perEquity Share, including premium of Rs. 129.50amountaggregatingEquityuptoShare,perRs. 27.90 Crores
		2. Upto 50,00,000 convertible warrants with rightto the warrant holder to apply for and be allottedOne (1) Equity Shares of Face value of Rs. 10/-each of the Company for each Warrants withinperiod of Eighteen (18) months from the date ofallotment of warrants at the price of Rs. 139.50warrantconvertibleeachperintoorexchangeable for 1(one) Equity Share of facevalue of Rs. 10/- each at premium of Rs. 129.50amountaggregatingEquityuptoShare,perRs.69.75 Crores
	4. AdditionaldetailscaseinofPreferential Issue
	i, Name of the Investor	Ipea Laboratories Limited
	ii. Post allotment of securities - outcomeof the subscription,issue price / allotted price (incase of convertibles), number ofinvestors	Pre-issuePost IssueSharesShares%%26.581,46,24,92376,24,92340.9826.581,46,24,92376,24,92340.98
	iii. In case of convertibles - intimation]on conversion of securities or on lapse of the tenure of the instrument	The Warrants proposed to be issued would beconvertible into Equity Shares in one or moretranches, at the option of the proposed allottee,within a period of 18 months of its allotment
5.	Anyterminationcancellationorof}proposalissuancesecuritiesforofincluding reasons thereof	Not Applicable